Search results
Intra-Cellular Therapies (NASDAQ:ITCI) Given New $107.00 Price Target at Canaccord Genuity Group
ETF DAILY NEWS· 5 days agoIntra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its target price increased by Canaccord Genuity Group from $100.00 to $107.00 in a research note
Taysha Gene Therapies Inc (TSHA) Shares Rise Despite Market Challenges – News Heater
NewsHeater· 5 days agoTaysha Gene Therapies Inc (NASDAQ: TSHA) has seen a rise in its stock price by 2.85 in relation to its previous close of 2.46. Is It Worth Investing in Taysha Gene Therapies ...
Insider Selling: Mates Sharon, Intra-Cellular Therapies Inc [ITCI] Chairman, President & CEO...
Knox Daily· 4 days agoUpon closing the transaction, the insider’s holdings decreased to 7,345 shares, worth approximately $0.0. As published in their initiating research note from Robert W. Baird ...
Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by Cantor Fitzgerald
ETF DAILY NEWS· 3 days agoCantor Fitzgerald’s price objective indicates a potential upside of 66.37% from the stock’s previous close. Several other equities analysts have also weighed in on the company ...
Weight loss drugs like Wegovy have taken the country by storm. But who can afford them?
USA TODAY· 4 days agoPatients like Price are struggling to afford a blockbuster class of weight-loss medications called...
As ketamine therapy booms, industry insiders worry about patient safety
Market Watch· 4 days agoThe incident raises broader questions about at-home ketamine therapy, the doctors wrote. Guidelines...
Cartesian Therapeutics (NASDAQ:RNAC) Price Target Raised to $54.00 at HC Wainwright
ETF DAILY NEWS· 6 days agoCartesian Therapeutics (NASDAQ:RNAC – Get Free Report) had its price target raised by research analysts at HC Wainwright from $2.00 to $54.00 in a research note< ...
Protara Therapeutics (NASDAQ:TARA) PT Raised to $30.00
ETF DAILY NEWS· 5 days agoProtara Therapeutics (NASDAQ:TARA – Get Free Report) had its price objective increased by Oppenheimer from $26.00 to $30.00 in a research note issued on ...
Cullinan Oncology, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest
ETF DAILY NEWS· 4 hours agoJonestrading lifted their price objective on Cullinan Oncology from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. William ...
Pfizer hemophilia gene therapy arrives in US to uncertain future
BioPharma Dive via Yahoo Finance· 3 days ago“The handwriting is on the wall regarding Roctavian,” Piper Sandler analyst Christopher Raymond...